Laurus Labs (LAURUSLABS) | Stock Overview & Key Data
Laurus Labs Performance Comparison
Stock Range
Today's Range
Low: ₹826.20
High: ₹849.80
on September 29, 2025
52 Week Range
Low: ₹427.05
High: ₹944.00
on October 7, 2024
on September 19, 2025
All-Time High: ₹944.00 on September 19, 2025
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Market Cap
INR455.7B
EPS
9.41
P/E Ratio (TTM)
88.45
Forward P/E
35.61
P/B Ratio
10.04
PEG Ratio
0.07
Div. Yield
0.18%
ROE
7.79%
Beta
0.332
Debt to Equity
60.05
Financial Highlights
Profitability
Gross Margin
59.39%
Operating Margin
16.90%
Profit Margin
8.58%
Returns and Earnings
Return on Assets (TTM)
3.84%
Return on Equity (TTM)
7.79%
EBITDA
INR13.4B
Net Income (TTM)
INR5.1B
Growth
Revenue (TTM)
Revenue Per Share (TTM)
INR109.94
Quarterly Revenue Growth (YoY)
31.40%
Quarterly Earnings Growth (YoY)
1,203.10%
Dividend Information
Last 12-Month Dividend
₹1.20
Current Dividend Yield
0.18%
3-Year Average Dividend Yield
0.16%
3-Year Average Annual Dividend
₹1.33
3-Year Total Dividends
₹4.00
Ex-Dividend Date
May 9, 2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Laurus Labs LAURUSLABS | 455.69B Large-cap | -10.71% | -4.18% | 22.33% | 35.38% | 35.19% | 79.18% | 62.24% | 196.88% |
| Sun Pharmaceutical SUNPHARMA | 3.84T Large-cap | -4.18% | -0.85% | -4.98% | -9.79% | -16.05% | -18.58% | 67.26% | 213.02% |
| Divi's Laboratories DIVISLAB | 1.52T Large-cap | -8.23% | -8.09% | -14.00% | -2.56% | -6.31% | 4.24% | 53.55% | 85.63% |
| Cipla CIPLA | 1.23T Large-cap | -4.85% | -5.09% | -0.75% | 1.57% | 1.35% | 4.16% | 34.48% | 93.97% |
| Torrent TORNTPHARM | 1.23T Large-cap | -1.88% | -1.22% | 10.50% | 10.62% | 4.17% | 2.25% | 128.29% | 26.40% |
| Dr. Reddy's DRREDDY | 1.04T Large-cap | -5.19% | -0.80% | -5.18% | 7.60% | -8.47% | -7.18% | 44.51% | 22.56% |
Ownership & Short Interest
Insider Ownership
32.16%
Institutional Ownership
43.84%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
2M
Average 90-Day Volume
2M
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is LAURUSLABS's 52-week high and low?
- In the last 52 weeks, Laurus Labs reached a high of ₹944.00 (on September 19, 2025) and a low of ₹427.05 (on October 7, 2024).
- What is the market cap and P/E ratio for LAURUSLABS?
- Curious about Laurus Labs's size and valuation? Its market capitalization stands at 455.69B. When it comes to valuation, the P/E ratio (trailing twelve months) is 88.45, and the forward P/E (looking ahead) is 35.61.
- Does LAURUSLABS pay dividends? If so, what's the yield?
- Yes, Laurus Labs is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 0.18%, and the company has paid an average of ₹1.33 per share annually over the past 3 years.
- Who are Laurus Labs's main competitors or similar companies to consider before investing?
When looking at Laurus Labs, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA3.84T Healthcare Drug Manufacturers - Specialty & Generic -18.58% 67.26% Divi's Laboratories
DIVISLAB1.52T Healthcare Drug Manufacturers - Specialty & Generic 4.24% 53.55% Cipla
CIPLA1.23T Healthcare Drug Manufacturers - Specialty & Generic 4.16% 34.48% Torrent
TORNTPHARM1.23T Healthcare Drug Manufacturers - Specialty & Generic 2.25% 128.29% Dr. Reddy's
DRREDDY1.04T Healthcare Drug Manufacturers - Specialty & Generic -7.18% 44.51% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Laurus Labs Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Laurus Labs's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 7.79%, the Debt to Equity ratio from the most recent quarter is 60.05, and its Gross Profit Margin stands at 59.39%.
- What is the recent revenue and earnings growth for LAURUSLABS?
- Looking at Laurus Labs's growth, its revenue over the trailing twelve months (TTM) was INR59B. Compared to the same quarter last year (YoY), quarterly revenue grew by 31.40%, and quarterly earnings saw a YoY growth of 1,203.10%.
- How much of LAURUSLABS stock is held by insiders and institutions?
- Wondering who owns Laurus Labs stock? Company insiders (like executives and directors) hold about 32.16% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 43.84%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.